Please use this identifier to cite or link to this item:
|Title:||Retrospective quality control review of FDG scans in the imaging sub-study of PALETTE EORTC 62072/VEG110727: a randomized, double-blind, placebo-controlled phase III trial|
|Authors:||Hristova, Ivalina;Boellaard, Ronald;Vogel, Wouter;Mottaghy, Felix;Marreaud, Sandrine;Collette, Sandra;Schöffski, Patrick;Sanfilippo, Roberta;Dewji, Raz;van der Graaf, Winette;Oyen, Wim J G|
|Abstract:||(18)F-Labelled fluorodeoxyglucose (FDG) can detect early changes in tumour metabolism and may be a useful quantitative imaging biomarker (QIB) for prediction of disease stabilization, response and duration of progression-free survival (PFS). Standardization of imaging procedures is a prerequisite, especially in multicentre clinical trials. In this study we reviewed the quality of FDG scans and compliance with the imaging guideline (IG) in a phase III clinical trial.|
|Appears in Collections:||European Journal Of nuclear medicine _ molecular Imaging 2015|
Items in HannanDL are protected by copyright, with all rights reserved, unless otherwise indicated.